Answers are grounded in this paper and cite their sources.
Review highlights advanced nanodrug delivery systems for treating endometrial cancer, suggesting innovative strategies for improved outcomes.
Endometrial cancer (EC) is a group of epithelial malignant tumors that occur in the endometrium. Traditional therapies in clinical practice often face multiple challenges, including tumor recurrence, local invasion, distant metastasis, the development of drug resistance, and significant toxic side effects. Nanoparticles (NPs) have unique size advantages and extensive modifiability. They can achieve precise targeting of diseases to reduce toxicity, increase efficacy, inhibit metastasis, and combat drug resistance. This has brought new hope for the treatment of EC. While most relevant reviews cover a wide spectrum of gynecological disorders, there remains a lack of detailed and systematic elaboration on the application of NPs in the therapy of EC. The present review focuses on the application value of nanodrug delivery systems (NDDSs) in the treatment of EC, summarizes representative nanomaterials developed for EC treatment, and highlights the advanced delivery strategies and corresponding therapeutic applications of NDDSs for EC. In the concluding section, we summarize the current limitations of NDDSs in the EC field, map out a translational path from bench to bedside, and highlight safety and efficacy as pivotal elements, aiming to provide practical solutions for future medical-technology innovation.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: